Chemotherapy response monitoring with DNA methylation-based ctDNA tumor fraction: Evidence from a real-world cohort of patients with advanced common solid malignancies
On-treatment changes in methylation-based TF in chemotherapy-treated patients are associated with long-term outcomes. CtDNA monitoring offers an opportunity to rapidly evaluate therapy efficacy, potentially improving clinical decision-making regarding benefit vs toxicity and long-term patient outcomes.
Authors
- Arielle J. Medford (ORCID: https://orcid.org/0000-0002-0829-183X)
- Alessandro Russo (ORCID: https://orcid.org/0000-0002-3365-1972)
- Roberto Borea (ORCID: https://orcid.org/0000-0001-5403-0916)
- Carin R. Espenschied (ORCID: https://orcid.org/0000-0001-6108-7785)
- Bernard Herrman
- Katie Quinn (ORCID: https://orcid.org/0009-0006-6905-2257)
- Jiemin Liao (ORCID: https://orcid.org/0000-0001-6848-5532)
- Kimberly C. Banks (ORCID: https://orcid.org/0000-0002-1290-3114)
- Sean Gordon (ORCID: https://orcid.org/0000-0003-3431-5804)
- Christian Diego Rolfo (ORCID: https://orcid.org/0000-0002-7860-8417)
- Moh’d Khushman (ORCID: https://orcid.org/0000-0002-3095-5073)
- Jing Wang (ORCID: https://orcid.org/0000-0002-9538-8452)
Institutions
- Humanitas University (IT)
- Harvard University (US)
- Washington University in St. Louis (US)
- The Ohio State University Wexner Medical Center (US)
- Massachusetts General Hospital (US)
- Guardant (United States) (US)
Publication Details
- Journal
- The Journal of Liquid Biopsy
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1016/j.jlb.2025.100442
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 0.00